Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine maintenance of response in adults with ADHD
2007-007672-41Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Atomoxetine maintenance with Placebo maintenance (2 arms). Primary endpoint: Primary efficacy endpoint. Started Feb 2008; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2007-007672-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007672-41.